Research Topics
| Marc C ChamberlainSummaryAffiliation: University of Washington Country: USA Publications
| Collaborators
|
Detail Information
Publications
Sequential salvage chemotherapy for recurrent intracranial hemangiopericytomaMarc C Chamberlain
Department of Neurology and Neurological Surgery, University of Washington, Seattle, Washington 98102, USA
Neurosurgery 63:720-6; author reply 726-7. 2008..We undertook a retrospectively collected case series of recurrent intracranial HPCs treated with salvage chemotherapy with the primary objective of evaluating progression-free survival...- Bevacizumab for recurrent alkylator-refractory anaplastic oligodendrogliomaMarc C Chamberlain
Department of Neurology and Neurosurgery, University of Washington Fred Hutchinson Cancer Center, Seattle, Washington, USA
Cancer 115:1734-43. 2009..There is no standard therapy for alkylator-resistant AO, and hence a need exists for new therapies... - Salvage therapy with single agent bevacizumab for recurrent glioblastomaMarc C Chamberlain
Department of Neurology and Neurosurgery, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1023, USA
J Neurooncol 96:259-69. 2010..5 months). 6-month and 12-month PFS were 42% and 22% respectively. Single agent bevacizumab demonstrated efficacy and acceptable toxicity in this cohort of adults with recurrent alkylator-refractory GBM... - CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendrogliomaMarc C Chamberlain
Department of Neurology and Neurological Surgery, University of Washington, Seattle, WA, USA
J Neurooncol 89:231-8. 2008..A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS)... - Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymomaMarc C Chamberlain
Department of Neurology and Neurosurgery, University of Washington Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Cancer 115:4775-82. 2009.... - Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-CMarc C Chamberlain
Department of Neurology, Division of Neuro Oncology, University of Washington, Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, 825 Eastlake Avenue E, Seattle, WA 98109, USA
J Neurooncol 91:271-7. 2009..The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM)... - Radiographic patterns of relapse in glioblastomaMarc C Chamberlain
Division of Neuro Oncology, Department of Neurology and Neurological Surgery, Fred Hutchinson Research Cancer Center, University of Washington, 895 Eastlake Ave, POB Box 19023, MS G4 940, Seattle, WA 98109 1023, USA
J Neurooncol 101:319-23. 2011..A majority of adult patients with GBM at diagnosis manifest MRI-defined local disease and maintain this pattern notwithstanding multiple recurrences and treatment with bevacizumab... - Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeabilityMarc C Chamberlain
Department of Neurology and Neurological Surgery, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA 98109 1023, USA
Expert Rev Neurother 10:547-61. 2010.... - Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomasMarc C Chamberlain
Department of Neurology and Neurological Surgery, University of Washington, Seattle, Washington, 98109, USA
Cancer 116:3988-99. 2010.... - Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytomaMarc C Chamberlain
Department of Neurology and Neurological Surgery, University of Washington Fred Hutchinson Cancer Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Seattle, WA 98109 102, USA
J Neurooncol 91:359-67. 2009..Survival ranged from 2 to 23 months (median: 9.0). 6-month and 12-month PFS were 60 and 20%, respectively. Bevacizumab demonstrated efficacy and acceptable toxicity in this cohort of adults with recurrent alkylator refractory AA... - Brain metastases: a medical neuro-oncology perspectiveMarc C Chamberlain
Department of Neurology and Neurological Surgery, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA 98109 1023, USA
Expert Rev Neurother 10:563-73. 2010.... - Recurrent spinal cord glioblastoma: salvage therapy with bevacizumabMarc C Chamberlain
Department of Neurology and Neurological Surgery, Seattle Cancer Care Alliance, University of Washington Fred Hutchinson Cancer Research Institute, 825 Eastlake Ave E, POB 19023, MS G4940, Seattle, WA 98109 1023, USA
J Neurooncol 102:427-32. 2011..Overall median survival was 9 months (range of 5-13 months). Bevacizumab is well tolerated, has tolerable toxicity and apparent activity in this small cohort of adults with recurrent spinal cord glioblastoma... - Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomasMarc C Chamberlain
University of Washington, Department of Neurology Division of Neuro Oncology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, Seattle, WA 98109 1023, USA
Expert Rev Neurother 10:1537-44. 2010.... - Intradural intramedullary spinal cord metastasis due to mesotheliomaMarc C Chamberlain
Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington, Seattle, WA 98109 1023, USA
J Neurooncol 97:133-6. 2010..Cyberknife radiotherapy. Intramedullary spinal cord metastases, although rare, is increasingly recognized with spinal cord MRI. Treatment remains unsatisfactory as treatment with surgery or irradiation is only partially effective... - Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasiaMarc C Chamberlain
Department of Neurology and Neurological Surgery, University of Washington, DC, USA
J Neurooncol 93:229-32. 2009..A case series of gliomas treated with alkylator-based chemotherapy who subsequently developed myelodysplastic syndrome (tMDS) or acute myelocytic leukemia (AML)... - Temozolomide for recurrent low-grade spinal cord gliomas in adultsMarc C Chamberlain
Department of Neurology and Neurological Surgery, University of Washington, Seattle, Washington 98109 1023, USA
Cancer 113:1019-24. 2008..Therefore, a retrospective study of temozolomide (TMZ) in adults with recurrent low-grade spinal cord gliomas with a primary objective of determining progression-free survival (PFS) was performed... - Neoplastic meningitis-related prognostic significance of the Karnofsky performance statusMarc C Chamberlain
University of Washington, Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Mail Stop G 4940, Seattle, WA 98109 1023, USA
Arch Neurol 66:74-8. 2009..The prognostic significance of Karnofsky performance status in neoplastic meningitis (NM) has not been demonstrated in patient groups similarly matched for known prognostic variables... - Mechanisms of disease: temozolomide and glioblastoma--look to the futureMaciej M Mrugala
Department of Neurology, University of Washington Fred Hutchinson Cancer Research Center, Seattle, Washington 98106, USA
Nat Clin Pract Oncol 5:476-86. 2008..This Review summarizes new developments in treatment of glioblastoma and speculates on possible future treatment strategies for managing this aggressive cancer... - Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomasMarc C Chamberlain
Department of Neurology, University of Washington Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1023, USA
Cancer 113:2146-51. 2008..A phase 2 study was designed to estimate the 6-month progression-free survival of patients with recurrent, treatment-refractory, World Health Organization grade 1 meningiomas who were treated with interferon-alpha... - Adult primary intradural spinal cord tumors: a reviewMarc C Chamberlain
Department of Neurology Division of Neuro OncologyFred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Avenue East, POB 19023, MS G4940, Seattle, WA 98109 1023, USA
Curr Neurol Neurosci Rep 11:320-8. 2011..Treatment consists of surgical resection, and predictors of outcome include preoperative functional status, histologic grade of tumor, and extent of surgical resection... - Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytomaMarc C Chamberlain
Department of Neurology, University of Washington, Seattle, WA, USA
Cancer 112:2038-45. 2008..The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS)... - Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatmentMarc C Chamberlain
Department of Neurology and Neurological Surgery, Division of Neuro Oncology, University of Washington, Seattle, WA 98109 1023
Semin Oncol 36:S35-45. 2009..Until techniques capable of detecting NM early are developed, increased awareness of the disease and standardized evaluation are likely to have the greatest impact on improving diagnosis and implementing earlier treatment... - Adult primary spinal cord tumorsSean Grimm
University of Washington, Department of Neurology Division of Neuro Oncology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, POB 19023, MS G4940, Seattle, WA 98109 1023, USA
Expert Rev Neurother 9:1487-95. 2009..Primary treatment is surgery in essentially all spinal cord tumors, and predictors of outcome include preoperative functional status, histological grade of tumor and extent of surgical resection... - Antiangiogenic therapy for high-grade gliomasMarc C Chamberlain
University of Washington, Department of Neurology, Division of Neuro Oncology, Seattle, WA 98109, USA
CNS Neurol Disord Drug Targets 8:184-94. 2009..Gliomas and in particular high-grade gliomas (HGG) demonstrate when compared to other non-neural solid cancers amongst the highest levels of tumor angiogenesis (the formation of new blood vessels from pre-existing vasculature)... - Pseudoprogression: relevance with respect to treatment of high-grade gliomasJames Fink
Department of Radiology, University of Washington, Seattle, USA
Curr Treat Options Oncol 12:240-52. 2011..e. target) lesion stabilizes or diminishes in size on continued post-radiation (temozolomide) therapy as determined by follow-up radiologic imaging... - Anaplastic astrocytomas: biology and treatmentMarc C Chamberlain
University of Washington, Department of Neurology and Neurological Surgery, Division of Neuro Oncology, Fred Hutchinson Cancer Research Institute, Seattle, WA 98109 1023, USA
Expert Rev Neurother 8:575-86. 2008..This treatment paradigm varies considerably from actual practice... - Myelomatous meningitisMarc C Chamberlain
Department of Neurology, University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington 98109, USA
Cancer 112:1562-7. 2008..Myelomatous meningitis (MM) has been considered rare. The current study was performed to characterize the clinical presentation, treatment, and outcome of MM... - Risk of neoplastic meningitis following surgical resection of cerebellar metastasesMarc C Chamberlain
Department of Neurology and Neurosurgical Surgery, University of Washington, Fred Hutchinson Cancer Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, Seattle, WA 98109 1023, USA
J Neurooncol 89:105-7. 2008..Based on limited literature, an at risk group of patients for development of neoplastic meningitis (NM) are those with resected cerebellar parenchymal metastases... - Neoplastic meningitis: survival as a function of cerebrospinal fluid cytologyMarc C Chamberlain
Division of Neuro Oncology, Department of Neurology and Neurological Surgery, University of Washington Fred Hutchinson Cancer Research Institute, Seattle Cancer Care Alliance, Seattle, Washington, USA
Cancer 115:1941-6. 2009..This retrospective comparison evaluated survival in 2 well-matched cohorts of patients with neoplastic meningitis (NM) presenting with or without positive cerebrospinal fluid (CSF) cytology... - Neoplastic meningitisMarc C Chamberlain
Department of Neurology, Division of Neuro Oncology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington, Seattle, Washington 98109 1023, USA
Oncologist 13:967-77. 2008..Neoplastic meningitis (NM) is a common problem in neuro-oncology, occurring in approximately 5% of all patients with cancer... - Leptomeningeal metastasisMarc C Chamberlain
Department of Neurology, Fred Hutchinson Cancer Research Center, University of Washington, Neuro Oncology Program, Seattle, Wisconsin, USA
Curr Opin Oncol 22:627-35. 2010..Leptomeningeal metastasis occurs in approximately 3-5% of all patients with cancer. A contemporary literature review of methods of diagnosis and treatment of leptomeningeal metastasis was performed... - Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case seriesMarc C Chamberlain
Department of Neurology and Neurological Surgery, Division of Neuro Oncology, University of Washington Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
J Neurooncol 104:765-71. 2011.... - Leptomeningeal metastasisMarc C Chamberlain
Department of Neurology and Neurological Surgery, Division of Neuro Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1023, USA
Semin Neurol 30:236-44. 2010.... - High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphomaMarc C Chamberlain
Department of Neurology and Neurological Surgery, Division of Neuro Oncology Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
Neuro Oncol 12:736-44. 2010..Overall, PFS ranged from 2 to 80 months (median 21.0). HD-MTX/rituximab and deferred radiotherapy demonstrated similar or better efficacy similar to other HD-MTX-only regimens and reduced time on therapy on average to 6 months... - Neurotoxicity of cancer treatmentMarc C Chamberlain
Department of Neurology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, MS G4 940, POB 10923, Seattle, WA 98109, USA
Curr Oncol Rep 12:60-7. 2010..Peripheral nervous system disorders (ie, steroid myopathy, spindle poison, or platinum neuropathy) are predominantly treatment related and respond best to discontinuation of the neurotoxic agent... - Leptomeningeal metastasisMarc C Chamberlain
Department of Neurology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
Curr Opin Neurol 22:665-74. 2009..Leptomeningeal metastasis occurs in approximately 5% of all patients with cancer. This review summarizes recent literature regarding methods of diagnosis and treatment of leptomeningeal metastasis... - Chemotherapy for brain metastases due to lung cancer and melanomaMarc C Chamberlain
Department of Neurology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1023, USA
Cancer Treat Res 136:199-213. 2007 - Neurolymphomatosis: a rare metastatic complication of diffuse large B-Cell lymphomaMarc C Chamberlain
Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Institute, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Avenue East, Mailstop G 4940, PO Box 19023, Seattle, WA 98109 1023, USA
J Neurooncol 95:285-8. 2009..Neurolymphomatosis, although rare, is increasingly recognized with peripheral and central nervous system MRI. Treatment remains unsatisfactory as treatment with methotrexate-based chemotherapy and irradiation is only partially effective... - Salvage therapy with single agent bendamustine for recurrent glioblastomaMarc C Chamberlain
Department of Neurology and Neurosurgery, University of Washington Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Mailstop G4 940, Seattle, WA 98109, USA
J Neurooncol 105:523-30. 2011..Only one patient was progression-free at 6 months, triggering the stopping rule for futility. Bendamustine was reasonably well tolerated but failed to meet the study criteria for activity in adults with recurrent GBM...